Garg Pushkal's Form 4 filing
Alnylam Pharmaceuticals, Inc. (ALNY) · filed Nov 27, 2024
- Accession no.
- 0001735276-24-000107
- Filed
- Nov 27, 2024
- Trade date
- Nov 25-26, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions. Open-market sales total $422.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Garg PushkalCIK 0001829252 | Officer (CMO & EVP Dev & Med Affairs) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 25, 2024 | Common Stock | AGrant or awardAcquired | +3,434 | $0.00 | $0 | 19,139 | Direct | |
| Nov 26, 2024 | Common Stock | SSaleDisposed | −30 | $247.77F3 | −$7,433.1 | 19,109 | Direct | |
| Nov 26, 2024 | Common Stock | SSaleDisposed | −246 | $249.60F4 | −$61,401.6 | 18,863 | Direct | |
| Nov 26, 2024 | Common Stock | SSaleDisposed | −364 | $250.68F5 | −$91,247.52 | 18,499 | Direct | |
| Nov 26, 2024 | Common Stock | SSaleDisposed | −945 | $251.42F6 | −$237,591.9 | 17,554 | Direct | |
| Nov 26, 2024 | Common Stock | SSaleDisposed | −97 | $252.27F7 | −$24,470.19 | 17,457 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $247.76 to $248.67. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $249.00 to $250.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $250.05 to $251.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $251.07 to $252.06. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Referenced by the price of 1 transaction in Table I.
- F7
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $252.09 to $252.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Referenced by the price of 1 transaction in Table I.